A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Documents similaires

• Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
  par: Koichi Ikeda, et autres
  Publié: (2025)
• A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
  par: Chay Ngee Lim, et autres
  Publié: (2025)
• Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
  par: Jessica Ailani, et autres
  Publié: (2024)
• Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
  par: Dawn C. Buse, et autres
  Publié: (2024)
• Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
  par: Richard B. Lipton, et autres
  Publié: (2025)